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REVIEWARTICLE
Emerging therapies for mitochondrial disorders
Helen Nightingale,1 Gerald Pfeffer,1,2,3 David Bargiela,1 Rita Horvath1 and
Patrick F. Chinnery1,4,5
Mitochondrial disorders are a diverse group of debilitating conditions resulting from nuclear and mitochondrial DNA mutations
that affect multiple organs, often including the central and peripheral nervous system. Despite major advances in our understanding
of the molecular mechanisms, effective treatments have not been forthcoming. For over five decades patients have been treated with
different vitamins, co-factors and nutritional supplements, but with no proven benefit. There is therefore a clear need for a new
approach. Several new strategies have been proposed acting at the molecular or cellular level. Whilst many show promise in vitro,
the clinical potential of some is questionable. Here we critically appraise the most promising preclinical developments, placing the
greatest emphasis on diseases caused by mitochondrial DNA mutations. With new animal and cellular models, longitudinal deep
phenotyping in large patient cohorts, and growing interest from the pharmaceutical industry, the field is poised to make a
breakthrough.
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Introduction
Mitochondria are complex intracellular organelles that play
a central role in cell homeostasis (Wallace, 1999). They are
the principal source of intracellular energy, are intimately
involved in both calcium and free radical metabolism, and
they can trigger programmed cell death (apoptosis). Tissues
and organs that critically dependent on these functions bear
the brunt of the pathology in human mitochondrial dis-
eases, which often affect the nervous system, muscle and
endocrine organs (Pfeffer et al., 2012). Most mitochondrial
disorders are progressive and often result in disability and
doi:10.1093/brain/aww081 BRAIN 2016: 139; 1633–1648 | 1633
Received December 21, 2015. Revised February 11, 2016. Accepted February 26, 2016. Advance Access publication May 3, 2016
 The Author (2016). Published by Oxford University Press on behalf of the Guarantors of Brain.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse,
distribution, and reproduction in any medium, provided the original work is properly cited.
 by guest on A
ugust 5, 2016
http://brain.oxfordjournals.org/
D
ow
nloaded from
 
premature death. Therefore, although they are rare dis-
eases, with a minimum reported prevalence of 1 in 4300
(Schaefer et al., 2004), they have substantial impact on
families and healthcare services.
Most mitochondrial disorders are ultimately thought to
arise through a bioenergetic defect linked to a deficiency of
ATP synthesis. ATP synthesis is the final step of respiration,
which is carried out by five oxidative phosphorylation
(OXPHOS) complexes situated on the inner mitochondrial
membrane. Each complex has multiple protein subunits
encoded by two distinct genomes: nuclear chromosomal
DNA (nDNA), and the 16.5 kb mitochondrial genome
(mtDNA).
Pathogenic mtDNA mutations often cause a subset of
classical mitochondrial clinical syndromes (Chinnery and
Hudson, 2013). However, an increased number of multi-
system mitochondrial disorders are being described in the
literature, many of which are yet to be fully characterized
clinically and genetically. These include an emerging
myriad of nuclear encoded mitochondrial disorders
caused by mutations in some of the 1500 nuclear genes
thought to code for mitochondrial proteins (Chinnery and
Hudson, 2013). In the past, the phenotypic and genetic
diversity has made clinical diagnosis very challenging.
However, with international diagnostic standards (Wolf
and Smeitink, 2002), and the widespread availability of
molecular genetic techniques, an accurate diagnosis is less
challenging than before. Next generation sequencing is
revolutionizing the diagnostic approach, with multi-gene
panels, whole exome, and whole genome sequencing
increasing the pace of diagnosis, and probably reducing
the overall costs. As a consequence, more and more
patients are being diagnosed with a mitochondrial
disorder, placing even greater emphasis on developing
treatments.
A recent systematic review identified over 1300 reports
using a variety of approaches expected to bypass or en-
hance components of mitochondrial function. However,
the vast majority of these reports are open-labelled case
series with less than five subjects. Although 30 rando-
mized trials have been carried out to date, no treatment
has shown a clear cut benefit on a clinically meaningful
end-point (for reviews see Pfeffer et al., 2012; Kerr,
2013). It is therefore likely that components of the trad-
itional ‘mitochondrial cocktail’ do not have a major thera-
peutic impact on most mitochondrial diseases. There is
therefore a clear need for the field to ‘think outside the
box’ when developing new treatments, harnessing the mas-
sive increase in our understanding of mitochondrial disease
pathogenesis. After preclinical evaluation in cellular and
animal models, new treatments showing promise should
be studied in patients using a rigorous approach (Pfeffer
et al., 2013). This review focuses on these new develop-
ments, with a particular emphasis on mtDNA diseases,
which were previously thought to be intractable. Here we
critically appraise each approach, and highlight areas where
there is likely to be traction in the future. This is timely,
because both small and large pharmaceutical companies are
starting to see the potential market in developing treat-
ments for these so-far untreatable disorders.
Capitalizing on the unique
properties of mitochondria
Mitochondria have unusual characteristics that are poten-
tially targetable for treatment at the molecular level.
Mitochondria contain numerous copies of their genome,
and most patients with mtDNA disease harbour both
mutated and wild-type mtDNA (heteroplasmy) (Wallace,
1999). The proportion of mutated mtDNA needs to be
in excess to cause a biochemical defect of the respiratory
chain. This critical threshold varies from mutation to mu-
tation, and also between tissues and organs. This partly
explains the tissue selectivity and clinical heterogeneity of
mitochondrial disorders (Macmillan et al., 1993). The
overall amount of mtDNA within a cell is also tightly
regulated in a tissue-specific manner, and some tissues
(such as skeletal muscle) display a close correlation be-
tween mtDNA content and mitochondrial activity (Wang
et al., 1999). This complexity raises the possibility of
enhancing mitochondrial function by manipulating the
ratio of mutant to wild-type mtDNA, or by increasing
the amount of wild-type mtDNA. Targeting mutated
mtDNA is an alternative approach, although this would
need to be highly specific to avoid adverse effects on wild-
type genomes. The delivery of wild-type nDNA (Di Meo
et al., 2012; Bottani et al., 2014; Torres-Torronteras et al.,
2014) or mtDNA (Ellouze et al., 2008; Yu et al., 2012a,b)
using viral vectors is another possibility, or perhaps the
replacement of dysfunctional proteins via the cell nucleus,
hitch-hiking on the mitochondrial import mechanism
(Perales-Clemente et al., 2011). Moving away from the
two genomes, small molecule screens may enhance func-
tion of the respiratory chain, stem cell therapies could
correct enzyme defects due to nuclear gene defects
(Hirano et al., 2006; Hill et al., 2009; Halter et al.,
2011; Lenoci et al., 2011; Filosto et al., 2012; Sicurelli
et al., 2012; Hussein, 2013), and treatments aimed at
non-specifically preventing neurodegeneration may be the
way forward. Some of these approaches capitalize on the
‘uniqueness’ of mitochondria, where other approaches
build on knowledge acquired from rare and common
neurological disorders. Having an open mind is critical
at this stage—the first effective treatment may not come
from an obvious place. This review considers
each, structured into four sections (Fig. 1): manipulating
DNA; new protein delivery; small molecule pharmaceut-
icals; and finally, stem cell approaches. Our discussion
focuses on the likelihood of these treatments being used
in the clinic for patients with mitochondrial disease, and
does not discuss recent work aimed at preventing these
disorders.
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Nucleic acid-based
approaches
Several approaches, described below, have been developed to
manipulate or replace mutated nDNA and mtDNA. As for
all potential therapies, the multi-organ nature of mitochon-
drial disorders and difficulties of transferring therapies
across cellular and mitochondrial membranes without caus-
ing toxic effects (Mingozzi and High, 2011), makes thera-
peutic targeting difficult. However, as explored further
below, methods exist to overcome these difficulties including
the use of viral vectors (Mingozzi and High, 2011), harness-
ing allotopic expression (nuclear expression of mtDNA
encoded protein) (Farrar et al., 2013), or fusion of thera-
peutic molecules to targeting proteins (Iyer et al., 2009).
Mitochondrially-targeted nucleases
Restriction endonuclease approaches were developed to rec-
ognize specific DNA sequences, produce double-
stranded DNA breaks, and thereby initiate target molecule
degradation. Unlike other gene therapy approaches, restric-
tion endonucleases are not contingent on stable vector in-
tegration into the nuclear genome. In theory, a single
treatment could induce a stable modulation of mtDNA
heteroplasmy, correcting the biochemical defect within dis-
eased cells (Minczuk et al., 2008; Bacman et al., 2013;
Gammage et al., 2014). Restriction endonucleases recognize
a broad repertoire of mtDNA sequences (‘restriction sites’)
and some pathogenic mtDNA mutations add restriction
sites that restriction endonucleases specifically target.
The m.8993T4G mtDNA mutation causes Leigh syn-
drome or neuropathy ataxia retinitis pigmentosa, and mito-
chondrially-targeted restriction endonuclease SmaI has been
shown to selectively eliminate m.8993T4G from patient-
derived cybrid cells. Over time, the treatment resulted in
repopulation with wild-type mtDNA, and normalization
of cellular ATP content (Tanaka et al., 2002).
Unfortunately, a key limitation of restriction endonucle-
ases is that very few human pathogenic mutations create
restriction sites amenable to this form of targeted destruc-
tion. This can in part be overcome by restriction endonucle-
ases custom designed to bind specific DNA sequences
Mitochondrially-targeted nucleases 
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Figure 1 Overview of novel therapeutic approaches for the treatment of mitochondrial disorders. AICAR = 5-aminoimidazole-4-
carboxamide ribonucleotide; PAPR = poly adenosine diphosphate-ribose polymerase receptor; TP = thymidine phosphorylase.
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(Klug, 2010). A zinc finger nuclease (ZFN) consists of
tandem repeat zinc fingers, each binding approximately
three DNA bases, combined with a FokI endonuclease
domain functioning as the DNA cleavage module (Klug,
2010). Specificity is achieved through different combin-
ations of zinc fingers. ZFNs have also been shown to se-
lectively eliminate the m.8993T4G mutation in a cybrid
model (Fig. 2) (Minczuk et al., 2008). Early ZFNs caused
significant cytotoxicity, homodimerization (Ramalingam et
al., 2011) and off-target binding. This would be detrimen-
tal in vivo, thereby limiting their clinical use (Radecke et
al., 2010), but are being addressed by improved design
(Gammage et al., 2014). The architecture of dimeric
ZFNs ensures that the active cleavage reagent is only
assembled at desired restriction sites, overcoming targeting
difficulties and concerns about constitutive nuclease activity
(Gammage et al., 2014). Customized ZFNs targeted
to mitochondria cause shifts in heteroplasmy through the
selective degradation of mtDNA containing the
m.8993T4G point mutation, and the large scale
(4977 bp) mtDNA ‘common deletion’, which is the most
common cause of chronic progressive external ophthalmo-
plegia, Kearns-Sayre syndrome, and Pearson marrow pan-
creas syndrome (Gammage et al., 2014). This work opens
up the opportunity to develop a library of bespoke ZFNs
against more common pathogenic mtDNA mutations, but
the shifts in heteroplasmy have been limited to date.
Longer-term studies, particularly using animal models,
will hopefully show that ZFNs can improve biochemical
function in vivo—but this will be technically demanding,
not least because of the challenges delivering these agents at
an appropriate concentration to affected tissues.
When combined with a non-specific nuclease (e.g. FokI),
TALEs (transcription activator-like effectors) become target-
specific DNA nucleases (TALENs) (Christian et al., 2010).
TALENs are potentially much more potent than ZFNs, but
their larger size limits their use with adeno-associated viral
vectors (AAVs) (Ellis et al., 2013), TALEs contain repetitive
Figure 2 Endonucleases. Endonucleases are used to target specific sequences in mtDNA causing double-strand breaks and degradation of
mtDNA. For example the endonuclease ZFN has been shown to reduce mutation load in a cybrid model of Leigh and NARP syndrome, which are
caused by the mtDNA mutation m.8933T4G within the ATP6 domain. ZFN binds specifically to the mutant form of the mtDNA and the FOK1
endonuclease domain cleaves the DNA molecule, which is then degraded.
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domain modules, each of which bind individual nucleotides
(Moscou and Bogdanove, 2009), thus different domain
module combinations can be used to ensure specificity.
A recent report described the use of mitochondrially loca-
lized TALENs targeted for mtDNA species with the
‘common deletion’ (m.8483_13459del4977), and a separate
TALEN that recognizes a point mutation (m.14459G4A in
the MT-ND6 gene) in an osteosarcoma cybrid cell model
(Bacman et al., 2013). The TALEN markedly reduced the
level of deleted mtDNA species allowing compensatory mito-
chondrial biogenesis to preferentially restore wild-type
mtDNA (Bacman et al., 2013). In studies with the point
mutation, relative specificity was demonstrated for the
mutant over the wild-type sequence (Bacman et al., 2013).
Interestingly the heteroplasmy shift persisted after the
TALENs were no longer detectable, suggesting long-lasting
effects after a single treatment (Bacman et al., 2013).
However, the impact of the rapid reduction in mtDNA
copy number following TALEN treatment raises serious con-
cerns about their potential toxicity, not least because several
fatal mitochondrial diseases are caused by mtDNA deple-
tion. However, the co-induction of mitochondrial biogenesis
could circumvent this issue, but will need careful evaluation
in animal models before any clinical studies.
The most recent addition to this group of endonucleases
is Cas9 nuclease. Unlike the ZFN and TALE proteins that
target the FokI endonuclease, Cas9 is targeted using a
much smaller short RNA sequence CRISPR (Hsu et al.,
2014). This RNA sequence can more easily be altered to
change target site than for TALEs and distinct RNA se-
quences can be used target Cas9 to induce multiple
double-stranded DNA breaks (Hsu et al., 2014; Cox et
al., 2015). Furthermore this system is not hindered by con-
text-specific binding reported for ZFNs and TALENs (Hsu
et al., 2014; Cox et al., 2015). Although there has been
controversy surrounding this approach, recently Cas9/
CRISPR has been demonstrated to restore the weight loss
phenotype of a mouse model of fatal disease hereditary
tyrosinaemia type 1 (Yin et al., 2014).
The potential use of restriction endonucleases to prevent
germline transmission has also been investigated.
MitoTALENs have been demonstrated to reduce levels of
human mutated mtDNA responsible for Leber hereditary
optic neuropathy (LHON) and NARP (neurogenic muscle
weakness, ataxia, and retinitis pigmentosa) in oocytes
(Reddy et al., 2015).
Peptide nucleic acids
Sequence-specific peptide nucleic acids selectively bind
mutant mtDNA and induce direct mtDNA strand degrad-
ation (Mukherjee et al., 2008). Although conjugation with
Figure 3 Adeno-associated viral vectors expressing wild-type gene constructs. Gene constructs can be introduced into host cells by
AAV and transcribed within the nucleus of the host. The end product is a functional protein, which can replace or bypass dysfunctional proteins
resulting from mutations in the host’s nDNA or mtDNA.
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mitochondrial targeting peptides promotes importation and
successful targeting into human cells in culture (Chinnery et
al., 1999), this initially failed to modulate heteroplasmy in
patient-derived cell lines (Kyriakouli et al., 2008). In part
this is due to a failure to transmit the peptide nucleic acids
across the mitochondrial membrane, so techniques of tra-
versing the cell membrane are being explored, such as ‘cell
membrane crossing oligomers’ (Kyriakouli et al., 2008),
which possess greater polarity, and RNA vectors (Comte
et al., 2013). Although these examples show promise, evi-
dence for therapeutic benefit remains sparse despite nearly
two decades of research. Targeted delivery will be a
common problem, and potential toxic effects need to be
excluded in long-term animal studies. Again, limited avail-
ability of animal models of human mtDNA diseases has
hindered progress.
Manipulating tRNAs
The large array of pathogenic mtDNA mutations affecting
tRNA genes prompted the exploration of tRNA-targeted
therapies (Yarham et al., 2011). Of particular interest are
tRNA synthetases that catalyse the addition of specific
amino acid molecules to cognate tRNA molecules during
protein translation. Early work demonstrated that the over-
expression of cognate aminoacyl mt-tRNA synthetase sta-
bilized mt-tRNA (mitochondrial tRNA) molecules
(Rorbach et al., 2008). More recently overexpression of
human non-cognate mitochondrial leucyl tRNA synthetase
and its small carboxy-terminal domain were shown to par-
tially rescue the biochemical dysfunction secondary to mt-
tRNA defects (Hornig-Do et al., 2014; Perli et al., 2014).
Gene transfer using adeno-
associated viral vectors
Harnessing viral vectors to transfer wild-type genes into the
cell nucleus dates back to the late 1990’s. Although initial
excitement was tempered by the death of a patient in an
early clinical trial (Raper et al., 2003), much progress has
been made in developing new, less immunogenic vectors
such as AAV (Wang et al., 2012) (Fig. 3).
Gene therapy for nuclear-
mitochondrial disorders
Ethylmalonic encephalopathy classically has heterogeneous
phenotypes with neurological, gastrointestinal, metabolic
and psychiatric sequelae (Tiranti et al., 2004) and results
from mutations in the ETHE1 gene (Tiranti et al., 2004).
ETHE1 encodes a ubiquitous mitochondrial sulphur diox-
ygenase that detoxifies hydrogen sulphide (Tiranti et al.,
2004). AAV-mediated hepatic ETHE1 gene expression re-
stores sulphur dioxygenase activity in a murine model of
ethylmalonic encephalopathy, correcting biochemical
abnormalities within liver, muscle, and brain; and increas-
ing survival from a few weeks to more than 6 months
(Di Meo et al., 2012). However, targeting human skeletal
muscle and other large tissues is extremely challenging,
given currently achievable viral titres. Targeting the rela-
tively impenetrable blood–brain barrier presents another
hurdle in the treatment of nuclear-encoded mitochondrial
diseases. However, there are exceptions where the ap-
proach has real potential for therapeutic benefit in the
near future.
Mitochondrial neurogastrointestinal encephalopathy
(MNGIE) is a rare defect of the thymidine phosphorylase
encoding gene TYMP (Nishigaki et al., 2003). Mutations
in TYMP cause high circulating levels of thymidine, which
in turn lead to mtDNA depletion and the formation of sec-
ondary mtDNA deletions and point mutations. Treating a
single organ, such as the liver, has been proposed to gener-
ate enough enzyme to ‘detoxify’ the systemic circulation and
thereby prevent disease progression (Torres-Torronteras et
al., 2014). In keeping with this idea, the permanent and
dose-dependent reduction of systemic toxic metabolite
levels in a murine model of MNGIE has been demonstrated
with the construct, AAV2/8-hcTYMP, which possesses a
liver-specific promoter (Torres-Torronteras et al., 2014).
Interestingly, recent evidence that the liver can synthesize
potentially therapeutic thymidine phosphorylase levels has
prompted the suggestion that liver transplantation would
be an effective therapy for MNGIE (Boschetti et al., 2014).
The Harlequin mouse model of mitochondrial complex 1
deficiency results from a pro-viral X-linked gene insertion
causing severely reduced apoptosis-inducing factor 1 (AIF1)
expression. These mice exhibit retinal and optic nerve re-
spiratory chain complex 1 deficiency causing glial and
microglial cell activation, retinal ganglion loss and optic
atrophy. The intra-vitreal administration of an AAV2/
2_AIF1 vector has been shown to counteract these changes
(Bouaita et al., 2012).
Finally, mutations in the MPV17 gene result in a hepa-
tocerebral mtDNA depletion syndrome that is also poten-
tially amenable to gene therapy (Bottani et al., 2014).
MPV17 knockout (KO) mice exhibit hepatic mtDNA de-
pletion and liver failure when subjected to a ketogenic diet
(Bottani et al., 2014). This phenotype is rescued by AAV
viral vector expression of human MPV17 cDNA with a
hepatic specific promoter (Bottani et al., 2014). However,
it is unclear whether the tissue-specific expression of the
transgene will correct the cerebral disorder. This is critical
because the CNS features of the disorder are fatal.
Gene therapy for mitochondrial
DNA disorders
Delivering gene therapy into mitochondria presents an even
greater challenge. Many cells vulnerable to mitochondrial
disease contain thousands of mitochondria, and the mito-
chondrial membrane is relatively impermeable. There is
little evidence that AAVs penetrate into the mitochondrial
matrix, so achieving the high titres required to intercalate
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with multiple copies of mtDNA seems almost insurmount-
able at present. An alternative approach is to harness well-
established techniques for nuclear gene therapy to ‘allotopi-
cally express’ mtDNA encoded proteins. If carefully engin-
eered, and with a targeting peptide presequence, this has the
potential to deliver wild-type proteins to the mitochondrial
membrane.
After early in vitro work expressing the subunits of the
mitochondrial ATPase (Bokori-Brown and Holt, 2006),
several laboratories have focused on the allotropic expres-
sion of complex I subunits with a view to treating the most
common mtDNA disorder: LHON. The mtDNA
m.11778G4A mutation affects nicotinamide adenine di-
nucleotide (NADH) dehydrogenase subunit 4 (ND4 of
complex 1, and accounts for 50% of LHON patients).
Not surprisingly, this mutation has been the focus for most
of the studies to date. In vitro and preclinical work (Guy et
al., 2002; Qi et al., 2007; Ellouze et al., 2008; Yu et al.,
2012a,b) provide some evidence base for this approach,
and preparations for early phase clinical (Lam et al.,
2010; Bin, 2015; Vignal, 2015) studies are well under
way in the USA, China and Europe.
The allotopic expression of a synthetic ND4 gene is re-
ported to increase ATP synthesis in a human cell harbour-
ing the m.11778G4A mutation (Guy et al., 2002). More
recently, in murine LHON models (Qi et al., 2007; Ellouze
et al., 2008; Yu et al., 2012a,b), intraocular injection of
human nuclear ND4 gene constructs expressed by AAV has
been shown to be safe (Ellouze et al., 2008; Yu et al.,
2012a); non-mutagenic to host mtDNA (Yu et al., 2013);
prevent retinal ganglion cells loss; and improve optic atro-
phy and vision (Ellouze et al., 2008; Yu et al., 2012a).
However, as explored further below, this contradicts the
longstanding evidence of interspecies protein incompatibil-
ity (McKenzie et al., 2003; Perales-Clemente et al., 2011).
Furthermore, although the allotopically-expressed proteins
appear to be imported, it is not clear whether the new
peptides integrate within the respiratory chain (Figueroa-
Martinez et al., 2011). Indeed, one study demonstrated
that mitochondrially-encoded NADH (reduced nicotina-
mide adenine dinucleotide) dehydrogenase (with an add-
itional mitochondrial transduction domain) was expressed
in the nucleus and partially rescued the phenotype of cells
with a homoplasmic knockout mutation for mt-Nd6
(Perales-Clemente et al., 2011). However, the expressed
protein seemed to lie largely outside the outer mitochon-
drial membrane (Perales-Clemente et al., 2011). Despite
these concerns, groups in Miami (Lam et al., 2010) and
China (Bin, 2015) are currently recruiting for a trial to
examine intraocular AAV-ND4 for LHON. A further
safety trial is currently recruiting in France (Vignal, 2015).
Expression of non-mammalian genes
There is interest in using AAV expressing mature yeast
complexes (not troubled by issues of integration) to
bypass mutations in multi-subunit mammalian equivalents.
This ‘transkingdom approach’ has been shown to preserve
retinal ganglion cells, improve optic nerve function and im-
prove vision in a rotenone-induced LHON rodent model
(Marella et al., 2010; Chadderton et al., 2013). Lentiviral
vectors expressing a yeast alternative oxidase have also
been demonstrated to rescue COX (cytochrome c oxidase)
deficiency in a mouse model (El-Khoury et al., 2013).
Despite the emerging evidence supporting transkingdom
protein expression, it remains a contentious issue. The co-
evolution of nDNA and mtDNA has led to species-specific
genome compatibility (Kenyon and Moraes, 1997).
Incompatibilities between nDNA and mtDNA explain
why Human-Gorilla xenomitochondrial cybrids have a re-
spiratory chain deficiency (Barrientos et al., 1998), and in-
compatibles of interspecies mtDNA gene products
(McKenzie et al., 2003; Perales-Clemente et al., 2011), sug-
gest that caution is needed with this approach, which is
very much at the early preclinical phase.
Improving mitochondrial DNA copy
number in mitochondrial DNA
depletion syndromes
In vitro and preclinical evidence support the therapeutic po-
tential of increasing deoxyribonucleotides to treat rate auto-
somal recessive mtDNA depletion syndromes. One approach
involves deoxyribonucleoside supplementation, which
increased mtDNA levels (copy number) in primary cell cul-
tures from patients with deoxyguanosine kinase deficiency
due to DGUOK mutations (Bulst et al., 2009; Camara et
al., 2014). A similar effect has also been seen in an in vitro
model of MNGIE (Camara et al., 2014). Another strategy
involves inhibition of deoxyribonucleoside catabolism, which
has also been shown to improve mtDNA copy number in
vitro (Camara et al., 2014). More recently, deoxyribonucleo-
side supplementation in a knock-in mouse model of thymi-
dine kinase 2 (TK2) deficiency increased mtDNA copy
number, improved mitochondrial respiratory chain function,
and prolonged life span (Garone et al., 2014).
New protein delivery
Systemic protein delivery
The identification of a specific protein dysfunction or defi-
ciency resulting in mitochondrial disease has led to the pos-
sibility of protein replacement or the removal of
accumulated toxic metabolites.
In MNGIE, haemodialysis has been used to remove
toxins (Spinazzola et al., 2002) and the transfusion of
platelets (Lara et al., 2006) or erythrocyte-encapsulated
thymidine phosphorylase (EE-TP) has been explored as a
means of delivering exogenous thymidine phosphorylase
(Table 2) (Moran et al., 2008; Bax et al., 2013; Hussein,
2013). At present there is no convincing evidence of
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sustained clinical benefit from either approach. However,
drawing on experience from other inborn errors of metab-
olism such as adenosine deaminase deficiency (Bax et al.,
2007), direct enzyme replacement could proceed into early
phase studies in the short to medium term. Indeed, a recent
preclinical trial has demonstrated adequate safety of recom-
binant EE-TP in mice and beagle dogs (Levene et al., 2013).
However, the reported antibody generation (Levene et al.,
2013) may preclude long-term use, and based on experi-
ence with other rare inherited enzyme defects, this ap-
proach is likely to be extremely expensive.
Cellular and mitochondrial protein
delivery
Delivering proteins across the mitochondrial membrane is
challenging because of their hydrophobicity, but harnessing
endogenous mitochondrial import machinery provides a
solution.
The mitochondrial protein TFAM (transcription factor A,
mitochondrial) is important for mtDNA expression and
replication (Iyer et al., 2009). Treating LHON cybrids
with mitochondrially-targeted TFAM increased respiratory
chain protein levels and enhanced cellular respiration (Iyer
et al., 2009). Furthermore, the systemic injection of this
construct into mice increased aerobic respiration in
muscle and brain, and improved overall motor endurance
(Iyer et al., 2009). However, caution is needed when con-
sidering translation into human trials because transgenic
mice overexpressing TFAM show increased mtDNA copy
number, mtDNA deletions and respiratory chain defi-
ciency—all of which could lead to long-term toxicity
(Ylikallio et al., 2010). This work highlights the difficulty
in interpreting the results from different cellular and animal
models that can be misleading. Studying a new treatment in
a range of cellular and animal systems will reduce the
chance of inappropriately rejecting a treatment based on
adverse effects in one model. On the other hand, studying
more than one model will reduce the chance of pursuing a
drug that will never make it into clinical use.
Small molecule
pharmaceuticals
Future pharmaceutical development focusing on disease-
specific or patient-specific molecular targets aimed at boost-
ing residual mitochondrial function is likely to be more
successful than previous approaches, which were generally
based on a non-specific bypass or amelioration of defective
components of the respiratory chain.
Systematic screening of small molecules has recently
increased in popularity, in part driven by the widespread
availability of patient cell lines, and technological advances
in medium-to-high throughput screening (Golubitzky et al.,
2011; Pfeffer et al., 2013; Soiferman et al., 2014). AlthoughT
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the complexity of the diverse genotype–phenotype relation-
ship still complicates drug discovery (Macmillan et al., 1993;
Wallace, 1999; Wang et al., 1999; Koopman et al., 2012),
this could be circumvented by screening a panel of drugs on
specific patient cell lines, leading to a personalized or preci-
sion medicine approach (Koopman et al., 2012), which can
be optimized for testing in animals models then clinical stu-
dies (Koopman et al., 2012). So called ‘N-of-one’ clinical
trials provide one way of moving forward in patients, prov-
ing the drugs have a measurable effect in a short time period.
Induction of mitochondrial biogenesis
Bezafibrate
Several studies have focussed on peroxisome proliferator-
activated receptor (PPAR) gamma co-activator 1 alpha
(PGC-1, encoded by PPARGC1A) as a potential treatment
for mitochondrial disease. PGC-1 co-ordinates the vast ma-
jority transcriptional mitochondrial biogenesis regulation in
accordance with metabolic demand (Scarpulla et al., 2012).
The array of novel pharmaceuticals discussed below either
modulate PCG-1 mtDNA or protein expression or target
its downstream pathways (Fig. 4). Bezafibrate is pan-agonist
for the PPAR family of transcriptional factors. PPAR- ac-
tivation promotes mitochondrial biogenesis by upregulating
PPARGC1A gene expression (Kanabus et al., 2014).
Although bezafibrate was reported to increase COX activity
and ameliorate the disease phenotype in a muscle-specific
Cox10 knockout mouse (Wenz et al., 2008), this observa-
tion has been retracted. Bezafibrate was not effective in two
other murine models of COX deficiency Surf1 knockout
(Viscomi et al., 2011) or Deletor mice (Yatsuga and
Figure 4 Schematic representation of pharmaceutical modulators of mitochondrial biogenesis. There are multiple signalling
pathways involved in mitochondrial biogenesis. PGC-1 (encoded by PPARGC1A), which is a co-activator for a family of transcriptional factors
known as PPARs, co-ordinates via a cascade of nuclear encoded proteins the vast majority transcriptional mitochondrial biogenesis. Novel
pharmacological therapies aim to modulate PCG-1 mtDNA expression (e.g. PPAR) and protein expression or target downstream pathways.
Bezafibrate is pharmacological ligand for the transcriptional co-factor PGC-1. AICAR activates AMP-activated protein kinase (AMPK) and is
thought to modulate increased mitochondrial biogenesis through PGC-1. The natural polyphenol resveratrol activates sirtuin 1 (SIRT1). Sirtuins
are part of a group of oxidizing NAD-dependent protein deacetylases. Upon activation, for example, by PGC-1 or transcription factor A,
mitochondrial (TFAM) they promote mitochondrial respiratory chain activities and the transcription of genes modulating mitochondrial bio-
genesis and function. Nicotinamide riboside can be used to supplement NAD + levels. PARP1 functions as a NAD + consuming enzyme. Thus in
turn inhibition of PARP1 has been demonstrated to increase NAD + bioavailability and SIRT1 activity (not shown above) promoting oxidative
phosphorylation. Rapamycin inhibits mTOR, which in turn releases mTOR inhibition of autophagy. Cyclosporin A inhibits the mitochondrial
permeability transition pore (MPTP). Opening of the mitochondrial permeability transition pore is thought to deplete pyridine nucleotides thus
impairing mitochondrial oxidative respiration.
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Suomalainen, 2012). Bezafibrate induced hepatomegaly and
abnormal lipid metabolism is reported in Surf1 knockout
(Viscomi et al., 2011) and Deletor mice (Yatsuga and
Suomalainen, 2012). Importantly this does not appear to
occur at comparable doses in humans.
AICAR
5-Aminoimidazole-4-carboxamide ribonucleotide (AICAR) is
an adenosine monophosphate (AMP) analogue (Merrill et
al., 1997) causing AMPK to initiate catabolic mechanisms
to produce ATP and inhibit anabolic processes (Canto and
Auwerx, 2009), promote PPARGC1A gene transcription
(Terada et al., 2002) and PGC-1 activity by direct phos-
phorylation (Jager et al., 2007). AICAR has been shown to
increase mitochondrial biogenesis and ATP production
alongside decreasing reactive oxygen species human complex
I deficient fibroblasts (Golubitzky et al., 2011). AICAR also
causes partial correction of COX defects in mice (Viscomi et
al., 2011). The low apparent toxicity in humans supports its
further investigation (Dixon et al., 1991), although some
caution is needed as increased liver weight is suggested
with prolonged use in mice (Winder et al., 2000).
Resveratrol
Resveratrol is a natural polyphenol, known to increase
NAD+ (oxidized nicotinamide adenine dinucleotide) levels,
which activate the protein deacetylase SIRT1 (Kanabus et
al., 2014). SIRT1 activates PGC-1 by deacetylation spark-
ing a chain of signalling pathways promoting mitochondrial
biogenesis and function (Canto and Auwerx, 2009; Kanabus
et al., 2014).
Resveratrol activation of SIRT1 has been demonstrated
to restore normal function in human fibroblasts with
inborn errors of mitochondrial fatty acid b-oxidation
(Bastin et al., 2011). Such preclinical data have prompted
investigation of resveratrol for diseases with mitochondrial
pathogenesis such as Friedreich’s ataxia (Delatycki, 2012;
Yiu et al., 2013).
A recently completed open-label clinical pilot study inves-
tigating resveratrol in Friedrich’s ataxia has presented pre-
liminary data (full publication is awaited) showing
improvement in disease severity and oxidative stress mar-
kers (Delatycki, 2012; Yiu et al., 2013). Resveratrol is re-
ported to have only mild gastrointestinal side effects (Patel
et al., 2011).
Modulating NAD + bioavailability
The balance between NAD+ and NADH is crucial to the
process of oxidative phosphorylation. With increased
NAD+ bioavailability enhancing oxidative phosphorylation.
Indeed NAD+ supplementation with nicotinamide riboside
has produced promising biochemical and clinical improve-
ments in two mitochondrial myopathy murine models; a nu-
clear gene (Sco2) knockout/knockin mouse (Cerutti et al.,
2014), and the Deletor mouse possessing a nuclear gene mu-
tation resulting in mtDNA deletions (Khan et al., 2014).
PARP inhibitors
Inhibition of the NAD+ -consuming enzyme poly ADP (ad-
enosine diphosphate-ribose) polymerase 1 (PARP1) increases
NAD+ bioavailability, SIRT1 activity and subsequently oxi-
dative metabolism (Bai et al., 2011). There is convincing evi-
dence from murine models of myopathy (Cerutti et al., 2014)
and mitochondrial encephalopathy (Felici et al., 2014), of the
potential benefit of PARP inhibition in human mitochondrial
disease. Toxicity is also reported to be low (Tutt et al., 2010).
Inhibiting cytosolic translation and
autophagy
During starvation states damaged cellular components are
degraded to maintain cellular activity and viability (Kim et
al., 2011). This process termed autophagy is inhibited by
mammalian target of rapamycin (mTOR) (Kim et al., 2011).
Administration of the mTOR inhibitor rapamycin in a
murine model of Leigh syndrome delayed the onset of symp-
toms, reduced neuroinflammation and prevented brain le-
sions, leading to an increased life span (Johnson et al.,
2013). Although the safety profile and clinical use of rapa-
mycin is well documented, the associated immunosuppres-
sive effects, reduced wound healing and hyperlipidaemia
may limit its use for mitochondrial disease (Johnson et al.,
2013). In keeping with this, recent evidence in patient cell
lines also showed benefit from the partial inhibition of intra-
mitochondrial translation using cycloheximide, and the in-
hibition of autophagy by lithium chloride (Peng et al., 2015).
Inhibiting opening of the
mitochondrial permeability
transition pore
Opening of the mitochondrial permeability transition pore
(PTP) is thought to deplete pyridine nucleotides thus im-
pairing mitochondrial oxidative respiration. Cyclosporin A
inhibits the mitochondrial PTP and has been shown to
induce muscle regeneration, improve mitochondrial func-
tion, and suppress muscle apoptosis (Merlini et al., 2008)
in both a murine model of collagen VI-deficiency myopathy
and five patients with the same disorder. These findings
lend support to the use of cyclosporin A in other mitochon-
drial disorders such as LHON, where a clinical trial is cur-
rently recruiting patients (Milea, 2014). However, like
rapamycin, this widely used immunosuppressant may
have a non-acceptable side effect profile in chronic use.
Stem cell approaches
Substantial preclinical, and increasing clinical evidence
exists to support the use of stem cell therapies in several
neurological disorders where mitochondrial dysfunction
plays a role (e.g. Parkinson’s disease) (Lunn et al., 2011).
The proposed therapeutic mechanisms of stem cells are
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summarized in Fig. 5 (Parr et al., 2007; Kemp et al., 2010,
2014). Although not specific to mitochondrial dysfunction,
harnessing these approaches could be of therapeutic benefit.
Unfortunately the relative lack of animal models for pri-
mary mitochondrial disorders (Farrar et al., 2013) has lim-
ited investigation of stem cell therapies for mtDNA disease.
Exogenous stem cell therapy for
nuclear DNA mutations
A number of case reports and small case series, discussed
below, have described the effects of allogenic stem cell treat-
ment in patients with MNGIE (Table 2) (Hirano et al.,
2006; Hill et al., 2009; Lenoci et al., 2011; Filosto et al.,
2012; Sicurelli et al., 2012; Hussein, 2013). The rationale
behind the treatment is based on work where haemo/peri-
toneal dialysis or platelet transfusions reduced circulating
levels of toxic thymidine, presumably by introducing cells
with normal thymidine phosphorylase activity (Moran et
al., 2008; Bax et al., 2013; Hussein, 2013). Restoring thy-
midine phosphorylase activity in the bone marrow has been
shown to reduce toxic thymidine levels post-transplantation,
although the results were highly variable (Hirano et al.,
2006; Hill et al., 2009; Halter et al., 2011; Lenoci et al.,
2011; Filosto et al., 2012; Sicurelli et al., 2012; Hussein,
2013), and there is no convincing evidence that objective
clinical benefit was actually achieved.
Interestingly, a recent retrospective analysis of all the 24
patients with MNGIE known to undergo a haematopoietic
stem cell transplantation between 2005 and 2011 reported
that in the nine survivors, thymidine phosphorylase activity
rose from undetectable to normal levels (Halter et al., 2015).
Two trials at Columbia University, USA are currently re-
cruiting; one to map the natural history study of MNGIE
(Hirano, 2015a) and the other to asses the safety of stem cell
transplant for MNGIE in a proposed 12 patients (Hirano,
2015b). These should help inform future clinical trial design
and begin to address safety concerns highlighted by a con-
sensus report published by Halter et al. (2011).
Endogenous stem cells for
mitochondrial DNA mutations
There has been ongoing interest in the phenomenon of
‘gene shifting’ as a treatment for mitochondrial myopathy
(Clark et al., 1997; Spendiff et al., 2013). In patients with
Figure 5 Mechanism of action of stem cell therapies. Various mechanisms have been described for the therapeutic action of stem cells for
neurodegenerative conditions. These include secretion of neurotrophic factors and antioxidant enzymes such as superoxide dismutase, modu-
lation of the immune system, regeneration of neurons and more controversially, stem cell transdifferentiation into neurons. Recently mesen-
chymal stem cells have been demonstrated to fully fuse with native cells to form heterokaryons or partially fuse via junction formation and transfer
cellular organelles and factors.
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heteroplasmic mtDNA mutations, the muscle satellite cells
(myogenic stem cells) typically contain less mutated
mtDNA than mature post-mitotic skeletal muscle fibres.
Pharmacological methods and resistance exercise to
induce satellite cell proliferation and fusion with mature
muscle to deliver wild-type mtDNA into mature muscle
(Spendiff et al., 2013) have been demonstrated to reduce
mtDNA load in mature muscle (Clark et al., 1997) and
improve biochemistry. However, there is currently no evi-
dence of clinical benefit (Andrews et al., 1999). Recent
work using somatic cell nuclear transfer adds weight to
this approach, showing the correction of the metabolic dis-
turbance with minimal disruption of nuclear-mitochondrial
communication using induced pluripotent stem cells, albeit
in vitro (Ma et al., 2015).
A series of collaborative trials for patients with mtDNA
mutations (comprehensively reviewed) (Kerr, 2013) demon-
strated that endurance training increased work capacity
and mitochondrial enzyme activity, but did not reduce het-
eroplasmy. Thus the benefits in this context were unlikely
to be attributable to gene shifting and may simply reflect
increased oxygen delivery through the development of ca-
pillary networks. Moreover, there may be a finite capacity
for repair following induction of satellite cell proliferation
by these methods; raising concerns about long-term seque-
lae. Finally, any potential benefits are most likely help the
minority of patients with an isolated mitochondrial myop-
athy. Despite these concerns, there is currently an ongoing
crossover trial investigating exercise versus inactivity in a
cohort of patients with mitochondrial myopathy (Haller,
2012). This will hopefully provide a definitive answer to
the role of exercise training in this context.
Conclusion
The past 5 years have seen several new approaches de-
veloping through our understanding of the molecular
pathogenesis of mitochondrial diseases. For mtDNA dis-
orders, the early clinical studies attempting to harness
gene-shifting some 15 years ago have not really progressed
beyond early open labelled studies—probably because the
likely clinical impact is limited using current approaches.
Although intriguing, other molecular approaches directed
against mtDNA disease are very much at the preclinical
stage, and will require substantial development to improve
efficacy and ensure there is no substantial risk of toxicity
before human trials. From a clinical perspective, nuclear-
genetic enzyme defects show the greatest promise. Stem cell
therapy is already being used in specific contexts, and its
efficacy and safety being evaluated, and gene therapy trials
in mouse models show clear benefits. Unfortunately, each
one of these rare genetic diseases may require their own
proprietary approach, and the impact needs to be evaluated
long-term. Small molecules are attractive because they have
the potential to provide a more generic solution applicable
across the mitochondrial disease spectrum, and a greater
understanding of cell signalling pathways opens up several
unexpected disease targets. For some of these drugs, clinical
evaluation is imminent, particularly for those being repur-
posed or repositioned drugs such as bezafibrate. It is critical
at this stage that laboratory and clinical scientists work
closely with patient organizations to ensure that the ultim-
ate aims of therapy will actually tackle issues that are im-
portant to patients. Given limited resources, this will ensure
that new treatments improve quality of life—a prerequisite
if these treatments are going to be adopted by healthcare
systems worldwide.
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Literature search strategy
References for this Review were identified by searches of
PubMed for English language articles published between
1970 and September 2015 and references of relevant articles
and our personal libraries. The search terms ‘mitochondrial
disease’, ‘mitochondrial disorder’, ‘mitochondrial encephal-
opathy’, ‘Leber’s hereditary optic neuropathy’, ‘mitochon-
drial neurogastrointestinal encephalopathy’, ‘mitochondrial
encephalomyopathy, lactic acidosis and stroke-like episodes’,
‘neurogastrointestinal encephalopathy’, ‘myoclonic epilepsy
with ragged red fibers’, ‘Kearns Sayre syndrome’, ‘neur-
opathy, ataxia, and retinitis pigmentosa’, and ‘inborn error
metabolism’ were individually combined with ‘treatment’,
‘therapy’, ‘stem cell’, ‘stem cell transplant’, ‘bone marrow
transplant’, ‘genome’, ‘genetics’ and ‘gene therapy’ were
used. The final reference list was generated based on rele-
vance to the topics covered in this Review.
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